Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
Maria Teresa Petrucci, Paola Finsinger, Marta Chisini, Fabiana GentiliniDepartment of Cellular Biotechnology and Hematology, Sapienza University of Rome, ItalyAbstract: The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2014-07-01
|
| Edice: | Patient Preference and Adherence |
| On-line přístup: | http://www.dovepress.com/subcutaneous-bortezomib-for-multiple-myeloma-treatment-patientsrsquo-b-a17490 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|